

ASX Announcement 8 August 2018

Mach7 Partners with EnvoyAl to bring Al to Enterprise Imaging, VNA, and PACS

Melbourne, Australia; 8 August 2018: Mach7 Technologies Limited (Mach7 or the Company) (ASX:M7T) today announced it has entered into a distribution deal with Artificial intelligence (AI) platform provider, EnvoyAI. The deal facilitates Mach7 customer access to a wide range of AI applications available via the EnvoyAI platform within the Mach7 ecosystem. EnvoyAI's growing catalog of content includes 71 products from 30 algorithm development partners, including a large number which are already FDA cleared.

Misha Herscu, EnvoyAl's CEO shared, "During our first deployment of the EnvoyAl platform, at Wake Radiology in Raleigh, North Carolina, we easily integrated with the Mach7 VNA. There is a natural synergy between our products as we both have a deep commitment to open interfaces and interoperability. We are extremely excited to expand our partnership by working toward harmonising solutions for the imaging enterprise and rolling out the EnvoyAl platform and many Al solutions to current and future Mach7 customers."

As part of the deal, Mach7 and EnvoyAl are working toward building a direct integration between the Mach7 VNA and the EnvoyAl cloud, enabling a serverless deployment for existing Mach7 customers. This will eventually allow all Mach7 customers to test algorithms hosted on the EnvoyAl platform without any additional installation.

Mike Jackman, Mach7's CEO noted, "This partnership expands Mach7's ecosystem of Al applications, providing greater value to our customers. This is a great example of how the Mach7 Data Services Platform empowers our customers to leverage their data to extract meaningful clinical insights using the latest technology. Mach7's VNA and PACS customers can now have access to the powerful EnvoyAl tools to improve patient care."

About EnvoyAl

EnvoyAl facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAl provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAl assists research institutions and emerging Al companies in the translation and commercialization



ASX Announcement 8 August 2018

processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAl also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

About Mach7 Technologies

Mach7 Technologies (ASX:M7T) develops a secure data services platform that improves business, operational and patient outcomes. Mach7 provides an interoperable foundation to manage patient data and host an ecosystem of apps. Deliver solutions including PACS, enterprise imaging workflows, vendor neutral archiving (VNA), artificial intelligence (AI), clinical portals and care coordination. Reimagine, redefine, and reconstruct the best solution to connect and exchange health information without boundaries. Work smart with Mach7 in the cloud or onsite. Contact us to learn more.

For more information, contact:

Jenni Pilcher Andrew Keys

CFO, Company Secretary, Mach7 Investor Relations, Keys Thomas Associates

 $jenni.pilcher@mach7t.com \\ and rew.keys@keysthomas.com$